McKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, Misha Haq, Victoria Shi, Eric Koza, Melissa Ma, Rachel E Christensen, Sarah A Ibrahim, Jochen Schmitt, Lena Johannsen, Yuka Asai, Hilary E Baldwin, Enzo Berardesca, Brian Berman, Ana Carolina Vieira, Anna L Chien, David E Cohen, James Q Del Rosso, Jacquelyn Dosal, Lynn A Drake, Steven R Feldman, Alan B Fleischer, Adam Friedman, Emmy Graber, Julie C Harper, Yolanda R Helfrich, Gregor B Jemec, Sandra M Johnson, Rajani Katta, Peter Lio, Lisa E Maier, George Martin, Arielle R Nagler, Isaac M Neuhaus, Melis Palamar, Lawrence C Parish, Theodore Rosen, Stephen P Shumack, James A Solomon, Emil A Tanghetti, Guy F Webster, Allison Weinkle, Jonathan S Weiss, Edward J Wladis, Ian A Maher, Joseph F Sobanko, Todd V Cartee, Brian A Cahn, Murad Alam, Bianca Y Kang, Sanjana Iyengar, Noor Anvery, Erkan Alpsoy, Anthony Bewley, Clio Dessinioti, Alexander Egeberg, Burhan Engin, Harald P M Gollnick, Dimitrios Ioannides, Hei Sung Kim, Elizabeth Lazaridou, Ji Li, Hester Gail Lim, Giuseppe Micali, Clivia Maria Moraes de Oliveira, Lucero Noguera-Morel, Aurora Parodi, Markus Reinholz, Dae Hun Suh, Qiuning Sun, Esther J van Zuuren, Uwe Wollina, Youwen Zhou, Catherine Zip, Emily Poon, Ross Pearlman
IMPORTANCE: Inconsistent reporting of outcomes in clinical trials of rosacea is impeding and likely preventing accurate data pooling and meta-analyses. There is a need for standardization of outcomes assessed during intervention trials of rosacea. OBJECTIVE: To develop a rosacea core outcome set (COS) based on key domains that are globally relevant and applicable to all demographic groups to be used as a minimum list of outcomes for reporting by rosacea clinical trials, and when appropriate, in clinical practice...
April 24, 2024: JAMA Dermatology